Biotransformation and pharmacokinetic overview of enoximone and its sulfoxide metabolite
- 14 August 1987
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 60 (5) , 21-26
- https://doi.org/10.1016/0002-9149(87)90520-0
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Pharmacology of enoximoneThe American Journal of Cardiology, 1987
- Comparative acute hemodynamic effects of intravenous sodium nitroprusside and MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failureAmerican Heart Journal, 1985
- Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performanceThe American Journal of Cardiology, 1984
- Simultaneous analysis of a new cardiotonic agent, MDL 17,043, and its major sulfoxide metabolite in plasma by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1984
- Hemodynamic Effects of MDL 17,043, a New Cardiotonic Agent, in Patients with Congestive Heart FailureJournal of Cardiovascular Pharmacology, 1983
- Characterization of the Cardiovascular Activities of a New Cardiotonic Agent, MDL 17043 (1,3-Dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one)Journal of Cardiovascular Pharmacology, 1982
- Cardiovascular Properties of a New Cardiotonic AgentJournal of Cardiovascular Pharmacology, 1982
- A linear model of reversible metabolism and its application to bioavailability assessmentJournal of Pharmacokinetics and Biopharmaceutics, 1981
- Renal contribution to overall metabolism of drugs I: Conversion of benzoic acid to hippuric acidJournal of Pharmaceutical Sciences, 1972